Trial Profile

A Phase II Study of Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) of the Breast (TaCe)

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taletrectinib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms TaCe

Most Recent Events

01 May 2025 Planned initiation date changed from 1 Apr 2025 to 1 Apr 2026.
22 Nov 2024 Planned initiation date changed from 1 Oct 2024 to 1 Apr 2025.
09 Aug 2024 Status changed from not yet recruiting to suspended.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com